Search
Polihexanide
go.drugbank.com/drugs/DB12277ApprovedInvestigational[A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite.
Calcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawnCalcium carbimide, sold as the citrate salt, is an alcohol-sensitizing agent. … Calcium carbimide was conceived as an alternative for the treatment of alcoholism with a reduced side effect profile either when it is consumed accompanied by alcohol or without it.
Ferric pyrophosphate citrate
go.drugbank.com/drugs/DB13995Approved[L1419] It is also FDA approved since 2015.[FDA label] … Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.
Borneol
go.drugbank.com/drugs/DB11288ApprovedInvestigationalMixtures: Kwan Tak Hing Plaster - Pad-plsBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationaldue to non-selective steroidal activities [A275513, A275514]. … On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] … [A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be
Telotristat ethyl
go.drugbank.com/drugs/DB12095ApprovedTelotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. … [L43367] Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome.
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigational[L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.
Tafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigational[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Olive oil
go.drugbank.com/drugs/DB09567ApprovedInvestigationalUsed as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].